Strategic Partnerships Leverage CPP’s existing collaborations with Mallinckrodt, NCI, SWOG, and EMA/FDA to position joint venture or co-development opportunities, licensing discussions, and expanded access programs in GI cancers and pediatric oncology.

Fast Track & Orphan Capitalize on CPP-1X/sul’s FDA Fast Track and Orphan Drug designations to accelerate regulatory-friendly partnerships, funding discussions, and priority screening of related polyamine/inflammation pathways with potential pharma or biotech suitors.

Rare Disease Focus Target opportunities around familial adenomatous polyposis and early-onset diabetes programs where investors and collaborators seek disease-modifying prevention therapies, enabling license deals or milestone-driven collaborations.

Clinical Trial Footprint Explore opportunities to co-sponsor or align on ongoing PACES and other neuroblastoma, gastric cancer, and colorectal trials, offering strategic support, site networks, and patient recruitment partnerships to potential sponsors or CROs.

Small Biotech Advantage Position CPP as an agile, early-stage partner with a focused pipeline and accessible tech platform to attract mid- to late-stage biotech partners seeking lean, fast-moving collaboration on cancer prevention therapies.